<qa>  What is the name of the subjects who are considered by the Investigator to be free of signs and- Subjects who are considered by the Investigator to be free of signs and symptoms suggestive of progressive multifocal leukoencephalopathy and willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment including IFN-beta and glatiramer acetate while being treated with natalizumab during the study. 